{
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5230, 
        5236
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5666, 
        5672
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5731, 
        5737
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5237, 
        5246
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5332, 
        5341
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5673, 
        5682
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5738, 
        5747
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4514, 
        4537
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10202, 
        10222
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4702, 
        4729
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4734, 
        4738
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4897, 
        4901
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4991, 
        4995
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5085, 
        5089
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5179, 
        5183
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10045, 
        10049
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10079, 
        10083
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10113, 
        10117
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10147, 
        10151
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10181, 
        10185
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4739, 
        4761
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4902, 
        4924
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4996, 
        5018
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5090, 
        5112
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10050, 
        10072
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10084, 
        10106
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10118, 
        10140
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10152, 
        10174
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        860, 
        889
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        9937, 
        9972
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10014, 
        10040
      ]
    }
  ], 
  "Negative Findings Phraseology (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4957, 
        4969
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5051, 
        5063
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5145, 
        5157
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4807, 
        4817
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4970, 
        4980
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5064, 
        5074
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5158, 
        5168
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5221, 
        5229
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5657, 
        5665
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5748, 
        5755
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5400, 
        5407
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        7363, 
        7364
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5184, 
        5190
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10186, 
        10192
      ]
    }
  ], 
  "Positive Findings Phraseology (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4794, 
        4806
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5298, 
        5307
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5632, 
        5641
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6904, 
        6913
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6915, 
        6924
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4731, 
        4733
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4894, 
        4896
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4988, 
        4990
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5082, 
        5084
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        5176, 
        5178
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10042, 
        10044
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10076, 
        10078
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10110, 
        10112
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10144, 
        10146
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        10178, 
        10180
      ]
    }
  ], 
  "Synoptic Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        6697, 
        6714
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D1084007^CLIA|eMARCPlus|TN Cancer Registry|20170918000103||ORU^R01^ORU_R01|201709180001030001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-ES-012272^PathSys^44D1084007^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170906000000|||||||20170906000000|&Sentinel Lymph Node, Sentinel Lymph Node, Sentinel Lymph Node, Sentinel Lymph Node, Breast, Mastectomy - partial/simple, PQRS Breast Cancer Resection|1588658181^^^^^^MD^^CMS^D^^^NPI||||||20170908000000|||F||||||C50.512^Malignant neoplasm of lower-outer quadrant of left female breast^I10~C50.112^Malignant neoplasm of central portion of left female breast^I10~D05.12^Intraductal carcinoma in situ of left breast^I10~C77.3^Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes^I10|1285672592&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe patient's name is \"\" identified by requisition and specimen container labels. 1. Received in formalin in a container labeled with the patient's name and \"left axillary 1st sentinel node count 52,446\" is a 2.5 x 1.5 x 1 cm pink-tan and yellow candidate node. A portion of the parenchyma has been previously injected with blue-green dye. Cross sections comprising the entire specimen are submitted in cassettes 1A-F. (csb) 2. Received in formalin in a container labeled with the patient's name and \"2nd sentinel node left axilla\" is a 2 x 0.7 x 0.7 cm red-brown candidate node with loosely attached bits of fatty tissue. The candidate node is bisected and submitted in its entirety in cassettes 2A-B. (csb) 3. Received in formalin in a container labeled with the patient's name and \"3rd sentinel node left axilla\" is a 2.5 x 1.5 x 1 cm portion of disrupted fatty tissue containing a 1 x 0.9 x 0.7 cm pink-tan and red-brown candidate node. The candidate node is bisected and submitted in cassettes 3A-B. (csb) 4. Received in formalin in a container labeled with the patient's name and \"4th sentinel node left axilla\" is a 1.8 x 1.7 x 1.1 cm fatty portion of tissue containing a 1 x 1 x 0.8 cm pink and tan candidate node. The candidate node is trisected and submitted in its entirety in cassettes 4A-C. (csb) 5. Received in formalin in a container labeled with the patient's name and \"left breast\" is a 2,360 g left breast. Axillary contents are not present. The breast is 29.5 cm medial to lateral, 24.5 cm superior to inferior and is up to 8 cm anterior to posterior. Attached anteriorly is a 28 x 23 cm portion of pink and tan skin. Within the skin is an eccentric 1.5 cm in diameter pink slight raised nipple. The tan and brown wrinkled areola is 7 cm in diameter. Within the skin around the nipple are areas of previously injected blue dye up to 2 cm. The medial edge of the areola contains a 2.5 cm area of yellow-green ecchymosis. The posterior margin appears intact and contains adherent portions of brown muscle. The breast is inked as follows: Anterosuperior blue, anteroinferior green, posterior black, muscle orange. On section the soft yellow lobular parenchyma is comprised of less than 5% tan fibrous tissue. Within the junction of the inner quadrants is a 3 x 2.8 x 1.2 cm circumscribed tan mass which is 4 cm to the anterosuperior and anteroinferior margins of resection, 4.2 cm to the inked deep margin and muscle, is greater than 5% to the nipple and overlying skin. The mass is at the 9-o'clock position. Approximately 14 cm inferior and lateral to this mass and within the lower outer quadrant at approximately 4-o'clock is a 2 x 1.5 x 1 cm area of fibrosis with pink-tan and yellow discoloration consistent with site of previous biopsy. The biopsy site is 4 cm to the anteroinferior margin, 7 cm to the deep margin, greater than 5 cm to the nipple, 3 cm to the overlying skin and is well away from the remaining margins. Discrete residual tumor is not observed. Dissected from the fatty tissue and the lateral edge of the breast is a 1 x 0.8 x 0.7 cm tan and red-brown candidate node. Representative sections are submitted. Cassette summary:   5A, section of nipple   5B, section of deep margin and muscle over the circumscribed mass   5C-5E, sections of mass at 9-o'clock   5F-5I, sections comprising the entire area of fibrosis discoloration consistent with site of previous biopsy from the 4-o'clock position in the lower outer quadrant   5J-5K, upper inner quadrant   5L-5M, lower inner quadrant   5N-5O, upper outer quadrant   5P-5Q, lower outer quadrant   5R, candidate node, bisected. (CMB)\n\n\nPath report.relevant Hx\n\nHistory - Malignant neoplasm of lower-outer quadrant of left female breast (C50.512), Malignant neoplasm of upper-inner quadrant of left female breast (C50.212)\n\n\nPath report.final diagnosis\n\n1. Left axillary sentinel node #1 (biopsy):     One lymph node positive for metastasis (1/1).     Metastatic deposit 6 mm.     No extranodal extension identified. 2. Left axillary sentinel node #2 (biopsy):     One lymph node negative for metastasis (0/1). 3. Left axillary sentinel node #3 (biopsy):     One lymph node negative for metastasis (0/1). 4. Left axillary sentinel node #4 (biopsy):     One lymph node negative for metastasis (0/1). 5. Left breast (mastectomy):     Two foci of invasive ductal carcinoma with differing morphologies.     The mass from the 9-o'clock position is metaplastic carcinoma, mixed epithelial       and mesenchymal (chondroid type), grade 3, measuring 3 cm.     Lymphovascular invasion identified associated with this mass.     This mass does not extend to the margins of resection, closest margin is 4 cm,       anterior, superior and inferior.     Second mass at 4-o'clock measures 2 cm, invasive ductal carcinoma grade 2       with an associated small focus of ductal carcinoma in situ, intermediate       nuclear grade.     This mass measures 2 cm.     DCIS measures maximally 3 mm.     This mass does not extend to the margin, closest margin is 4 cm,       anterior/inferior for both invasive carcinoma and DCIS.     One intramammary lymph node free of metastasis (0/1).     Stage mpT2 (sn) pN1a. Prognostic markers from biopsies, 17-55-4544: Metaplastic tumor, present in node and 9:00 Estrogen Receptor (SP1): 0% of nuclei Progesterone Receptor (1E2): <1% of nuclei (negative) Ki-67 (30-9): 70-80% of nuclei (High labeling index) p53 (BP5311): 2+ nuclear staining ave, 60% of nuclei (positive); heterogenous ERBB2/Her2 (4B5): 0 (negative for overexpression)  Tumor at 4:00 Estrogen Receptor (SP1): 0% of nuclei Progesterone Receptor (1E2): 1+ nuclear staining, 5% of nuclei (weak) Ki-67 (30-9): 20-30% of nuclei (High labeling index) p53 (BP5311): 0% of nuclei (negative) ERBB2/Her2 (4B5): 0 (negative for overexpression)  CANCER CHECKLIST: INVASIVE CARCINOMA OF THE BREAST 3.000.001.1000043 SPECIMEN  Procedure: Total mastectomy (including nipple-sparing and skin-sparing mastectomy) TUMOR  Specify Clock Position of Tumor Site: 4 o'clock, 9 o'clock  Histologic Type: Metaplastic carcinoma, mixed epithelial and mesenchymal type  Glandular (Acinar) / Tubular Differentiation: Score 3 (< 10% of tumor area forming glandular / tubular structures)  Nuclear Pleomorphism: Score 3 (Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and bizarre forms)  Mitotic Rate: Score 3 (>=8 mitoses per mm2)  Overall Grade: Grade 3 (scores of 8 or 9)  Tumor Size: Greatest dimension of largest invasive focus > 1 mm (specify exact measurement in Millimeters (mm)):  Greatest dimension of largest invasive focus > 1 mm (specify exact measurement in Millimeters (mm)):: 30mm  Tumor Focality: Multiple foci of invasive carcinoma  Number of Foci: 2  Sizes of Individual Foci: 30, 20  Ductal Carcinoma In Situ (DCIS): DCIS is present in specimen, Negative for extensive intraductal component (EIC)  Size (Extent) of DCIS: Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation) in Millimeters (mm) is at least  Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation) in Millimeters (mm) is at least: 3mm  Architectural Patterns: Cribriform  Nuclear Grade (see Table 2 in CAP Protocol): Grade II (intermediate)  Necrosis: Not identified  Lobular Carcinoma In Situ (LCIS): No LCIS in specimen Tumor Extent  Skin Invasion: Invasive carcinoma does not invade into the dermis or epidermis  Skin Satellite Foci: Satellite foci not identified  Nipple DCIS: DCIS does not involve the nipple epidermis  Skeletal Muscle: No skeletal muscle is present Accessory Findings  Lymphovascular Invasion: Present  Dermal Lymphovascular Invasion: Not identified  Microcalcifications: Present in invasive carcinoma, Present in non-neoplastic tissue  Treatment Effect: No known presurgical therapy MARGINS  Invasive Carcinoma Margins: Uninvolved by invasive carcinoma  Distance from Closest Margin in Millimeters (mm): Distance is > 10 Millimeters (mm)  DCIS Margins: Uninvolved by DCIS (DCIS present in specimen)  Distance of DCIS from Closest Margin in Millimeters (mm): Distance is > 10 Millimeters (mm) LYMPH NODES  Number of Lymph Nodes with Macrometastases (> 2 mm): Specify number  Specify number: 1  Size of Largest Metastatic Deposit in Millimeters (mm): Specify (mm)  Specify (mm): 6mm  Extranodal Extension: Not identified  Number of Lymph Nodes Examined: Specify number  Specify number: 5  Number of Sentinel Nodes Examined: Specify number  Specify number: 4 PATHOLOGIC STAGE CLASSIFICATION (pTNM, AJCC 8th Edition)  TNM Descriptors: m (multiple foci of invasive carcinoma)  Primary Tumor (Invasive Carcinoma) (pT): pT2: Tumor > 20 mm but <= 50 mm in greatest dimension Regional Lymph Nodes (pN)  Modifier: (sn): Only sentinel node(s) evaluated. If 6 or more nodes (sentinel or nonsentinel) are removed, this modifier should not be used.  Category (pN): pN1a: Metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2.0 mm##\n\n\nPath report.microscopic examination\n\nMicroscopic examination is performed.\n\n\nPath report.site of origin\n\n1. Left axillary sentinel node #1 2. Left axillary sentinel node #2 3. Left axillary sentinel node #3 4. Left axillary sentinel node #4 5. Left breast tissue\n\n\nPath report.comments\n\nComments - The consensus within the department is that the metastasis in the node is from the larger, metaplastic carcinoma that demonstrates lymphovascular invasion.\n\n\n"
}